Main Article Content
Hyperandrogenism, a pathological condition caused by the effect of excess production of androgens on target organs and tissues, is one of the most common hormonal disorders observed in 5–20 % of women of reproductive age in the population and in 35–41 % of women suffering from infertility due to chronic anovulation. Hyperandrogenism is manifested by a combination of signs of damage to the skin and its appendages (seborrhea, acne, hirsutism, alopecia) and is defined by the term androgen-dependent dermopathy. In combination with other manifested signs of virilization, hyperandrogenism greatly aggravates socio-psychological, interpersonal relationships in most patients, often causing anxiety, depression, and a decrease in the quality of life. In this regard, the problem of hyperandrogenism is not only of medical but also of social significance. An urgent problem, widely studied by both endocrinologists and gynecologists, is a clinical variant of hyperandrogenism syndrome such as polycystic ovary syndrome. The article presents a discussion of the National Consensus on the management of patients with hyperandrogenism (2016), makes proposals and additions to the diagnosis and management of patients with syndromic forms of hyperandrogenism (pubertal dyspituitarism and its equivalent in adults — hypothalamic-pituitary dysfunction, nonclassical form of congenital dysfunction of the cortex adrenal glands). The key positions concerning the assessment of the state of carbohydrate metabolism in patients with polycystic ovary syndrome are considered. The regimens of treatment with antiandrogens and the expediency of their use in patients with polycystic ovary of endocrine origin are discussed.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: Hormone-modulating therapies for skin disease. J Am Acad Dermatol. 2019 Jun;80(6):1509-1521. doi: 10.1016/j.jaad.2018.08.061.
Tronko MD, Kaminsky VV, Tatarchuk TF, Dubossarskaya YO. National consensus on the management of patients with hyperandrogenism. Reproductive endocrinology. 2016;(30):3-13. doi: 10.18370/2309-4117.2016.30.8-18. (in Ukrainian).
Zeng X, Xie YJ, Liu YT, Long SL, Mo ZC. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020 Mar;502:214-221. doi: 10.1016/j.cca.2019.11.003.
Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific Publikation; 1992. 377-384 pp.
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098.
Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053. doi: 10.1002/14651858.CD003053.pub6.
Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertil Steril. 2017 Sep;108(3):426-441. doi: 10.1016/j.fertnstert.2017.06.026.
Broux E, Dewailly D, Catteau-Jonard S. Spironolactone as a relay for cyproterone acetate in hyperandrogenic women. Gynecol Obstet Fertil Senol. 2020 Feb;48(2):181-186. French. doi: 10.1016/j.gofs.2020.01.001.
Semenyna GB, Pankiv VI, Pashkovska NV, Korutko OO, Pankiv IV. Ovarian factors in the pathogenesis of chronic anovulation in polycystic ovary syndrome. Problems of endocrine pathology. 2020;1:65-71. doi:10.21856/j-PEP.2020.1.09. (in Ukrainian).
Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc. 2019 Jun 14;3(8):1545-1573. doi: 10.1210/js.2019-00078.
Castori M. Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations. ISRN Dermatol. 2012;2012:751768. doi: 10.5402/2012/751768.